{"id":2161,"date":"2026-06-08T17:00:00","date_gmt":"2026-06-08T20:00:00","guid":{"rendered":"https:\/\/sevenresiduosaude.com.br\/blog\/?p=2161"},"modified":"2026-06-08T17:00:00","modified_gmt":"2026-06-08T20:00:00","slug":"pgrss-sarcoma-partes-moles-adulto-leiomiosarcoma-lipossarcoma-ressecao-radioterapia-tki-pazopanib","status":"publish","type":"post","link":"https:\/\/sevenresiduosaude.com.br\/blog\/pgrss-sarcoma-partes-moles-adulto-leiomiosarcoma-lipossarcoma-ressecao-radioterapia-tki-pazopanib\/","title":{"rendered":"PGRSS sarcoma partes moles: adulto, RT, TKI"},"content":{"rendered":"

A regula\u00e7\u00e3o brasileira de RSS \u00e9 frequentemente desafiada por gestores de centros de oncologia sarcoma de partes moles STS adulto. Em 2026, h\u00e1 uma demanda crescente de hospitais com unidade STS adulto \u2014 leiomiossarcoma<\/strong> uterino + retroperitoneal + extremidade + IVC, lipossarcoma<\/strong> atypical lipomatous tumor + dedifferentiated + myxoid + pleomorphic + sclerosing, GIST gastrointestinal stromal tumor<\/strong> com KIT\/PDGFRA mutation + imatinib Glivec + sunitinib Sutent + regorafenib Stivarga + ripretinib Qinlock + avapritinib Ayvakit, sarcoma sinovial<\/strong> com SS18-SSX fusion + cabozantinib + tazemetostat Tazverik + larotrectinib Vitrakvi NTRK fusion, angiossarcoma<\/strong> + epithelioid + Kaposi + cardiac + hep\u00e1tico, rabdomiossarcoma adulto<\/strong> + alveolar\/embrion\u00e1rio\/pleom\u00f3rfico, MPNST malignant peripheral nerve sheath tumor<\/strong> + neurofibromatose-1, dermatofibrossarcoma protuberans DFSP<\/strong> com COL1A1-PDGFB fusion + imatinib Glivec, ressec\u00e7\u00e3o radical R0<\/strong> com margem 1-2cm + amputa\u00e7\u00e3o se necess\u00e1rio + reconstru\u00e7\u00e3o flap + endopr\u00f3tese oncol\u00f3gica Stanmore Implants\/Implantcast MUTARS R$ 80-150k para osteossarcoma + condrossarcoma membro inferior, radioterapia neoadjuvante\/adjuvante<\/strong> 50-66Gy + IORT intraoperat\u00f3ria + brachy intersticial Ir-192 R$ 4-12k\/dose + proton therapy Hitachi\/Varian, doxorrubicina + ifosfamida + dacarbazina + trabectedina Yondelis + eribulina Halaven + pazopanib Votrient + regorafenib Stivarga + sirolimus + olaratumab Lartruvo<\/strong> Lista C5 quimioter\u00e1picos + targeted. A consequ\u00eancia \u00e9 a urg\u00eancia de PGRSS dedicado para STS adulto<\/strong> \u2014 captura de doxorrubicina<\/strong> Adriamycin Lista C5 + ifosfamida<\/strong> + dacarbazina<\/strong> + trabectedina Yondelis<\/strong> PharmaMar Lista C5 R$ 18-35k\/dose para leiomio+liposarcoma + eribulina Halaven<\/strong> Eisai R$ 12-25k\/dose, pazopanib Votrient<\/strong> Novartis multikinase TKI + regorafenib Stivarga<\/strong> Bayer + sirolimus + olaratumab Lartruvo<\/strong> Lista C5 R$ 18-45k\/m\u00eas oral targeted, imatinib Glivec<\/strong> Novartis + sunitinib Sutent<\/strong> Pfizer + ripretinib Qinlock<\/strong> Deciphera + avapritinib Ayvakit<\/strong> Blueprint para GIST KIT+ Lista C5 R$ 12-30k\/m\u00eas \u00d7 meses-anos, larotrectinib Vitrakvi<\/strong> Bayer + entrectinib Rozlytrek<\/strong> Roche para NTRK fusion sarcoma sinovial Lista C5 R$ 35-65k\/m\u00eas, endopr\u00f3tese oncol\u00f3gica pedi\u00e1trica\/adulta extens\u00edvel<\/strong> Stanmore Implants Custom-Made + Implantcast MUTARS Growing + Howmedica Modular Replacement R$ 80-150k para salvamento de membro + livro RBI 10y, brachy intersticial Ir-192<\/strong> + IORT intraoperative radiotherapy Mobetron + Liac unit + livro CNEN-NN-3.05, gigli saw + bisturi Harmonic ACE \/ LigaSure Maryland<\/strong> R$ 3-5k descart\u00e1vel + CUSA Cavitron Integra<\/strong>. A realidade \u00e9 que STS adulto produz RSS de alt\u00edssima especializa\u00e7\u00e3o. PGRSS de STS adulto \u00e9 cadeia integrada<\/strong> \u2014 come\u00e7a no diagn\u00f3stico<\/strong> (RM + biopsia core+excisional + IHC + NGS painel + cytogenetic), passa pela terapia<\/strong> (ressec\u00e7\u00e3o R0 + RT neoadj\/adj + chemo + targeted) e termina no acompanhamento<\/strong> (RM trim + recidiva + endopr\u00f3tese revisional). O conjunto soma R$ 25.000-52.000\/m\u00eas<\/strong> que muitos gestores subestimam.<\/p>\n

Para o gestor que opera ou planeja unidade STS adulto, \u00e9 fundamental considerar a complexidade desde o in\u00edcio.<\/p>\n

Os procedimentos sarcoma partes moles e os RSS espec\u00edficos<\/h2>\n

Em uma opera\u00e7\u00e3o de qualquer porte, a cadeia gera RSS espec\u00edficos.<\/p>\n\n\n\n\n\n\n\n\n\n
Procedimento<\/th>\nInsumo cr\u00edtico<\/th>\nF\u00e1rmaco<\/th>\nRisco RSS<\/th>\n<\/tr>\n<\/thead>\n
Ressec\u00e7\u00e3o R0 + reconstru\u00e7\u00e3o<\/td>\nEndopr\u00f3tese Stanmore R$ 80-150k<\/td>\nN\u00e3o-aplic\u00e1vel<\/td>\nA4 + RBI 10y<\/td>\n<\/tr>\n
RT neoadj\/adj+IORT+brachy<\/td>\nAcelerador linear+Mobetron+Ir-192<\/td>\nN\u00e3o-aplic\u00e1vel<\/td>\nA4 + radioativo CNEN<\/td>\n<\/tr>\n
Doxo+ifosfamida+dacarbazina<\/td>\nBolsa infus\u00e3o CADD-Solis<\/td>\nLista C5 antineopl\u00e1sico<\/td>\nA4 + B Lista C5<\/td>\n<\/tr>\n
Trabectedina+eribulina<\/td>\nFrasco Lista C5 R$ 12-35k<\/td>\nYondelis+Halaven Lista C5<\/td>\nA4 + B Lista C5<\/td>\n<\/tr>\n
GIST imatinib+sunitinib<\/td>\nComprimido oral KIT TKI<\/td>\nGlivec\/Sutent\/Stivarga\/Qinlock<\/td>\nA4 + B Lista C5<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A soma t\u00edpica \u00e9 entre R$ 25.000-52.000\/m\u00eas<\/strong> em PGRSS dedicado de STS adulto vs R$ 9.000-20.000<\/strong> em PGRSS gen\u00e9rico subdimensionado.<\/p>\n

A ressec\u00e7\u00e3o R0 + reconstru\u00e7\u00e3o + endopr\u00f3tese oncol\u00f3gica: o procedimento de alt\u00edssima complexidade<\/h2>\n

A primeira camada do desafio \u00e9 a ressec\u00e7\u00e3o. Padr\u00e3o setorial inclui (a) ressec\u00e7\u00e3o radical R0<\/strong> com margem 1-2cm para STS extremidade + retroperitoneal + depend\u00eancia de localiza\u00e7\u00e3o; (b) reconstru\u00e7\u00e3o flap<\/strong> rotacional + livre microvascularizado VRAM\/gracilis\/ALT + enxerto cut\u00e2neo + tela biol\u00f3gica<\/strong> Strattice\/AlloDerm; (c) endopr\u00f3tese oncol\u00f3gica adulta extens\u00edvel<\/strong> Stanmore Implants Custom-Made + Implantcast MUTARS + Howmedica Modular Replacement R$ 80-150k para salvamento de membro; (d) amputa\u00e7\u00e3o supracondiliana\/desarticula\u00e7\u00e3o<\/strong> se necess\u00e1rio + pr\u00f3tese prot\u00e9tica; (e) bisturi Harmonic ACE \/ LigaSure Maryland<\/strong> + CUSA Cavitron Integra<\/strong> + gigli saw<\/strong>.<\/p>\n

Hospital com 30-100 STS adultos\/ano + 8-25 endopr\u00f3teses \u00d7 R$ 100k m\u00e9dio = R$ 800k-2.5M\/ano em endopr\u00f3tese + livro RBI. Como discutimos no post sobre PGRSS de pedi onc<\/a>, tecnovigil\u00e2ncia \u00e9 estruturante.<\/p>\n

A RT neoadj\/adj + IORT + brachy + proton: o est\u00e1gio radioter\u00e1pico<\/h2>\n

A segunda camada \u00e9 a RT. Padr\u00e3o setorial inclui (a) RT neoadjuvante<\/strong> 50Gy\/25 fra\u00e7\u00f5es 5 semanas pr\u00e9-op para reduzir tumor + facilitar R0; (b) RT adjuvante<\/strong> 60-66Gy\/30-33 fra\u00e7\u00f5es p\u00f3s-op para margem positiva + recidiva alta risco; (c) IORT intraoperative radiotherapy<\/strong> Mobetron IntraOp + Liac unit single-dose 10-20Gy intraoperat\u00f3rio; (d) brachy intersticial Ir-192<\/strong> R$ 4-12k\/dose com cateter HDR + livro CNEN-NN-3.05 + reten\u00e7\u00e3o 5y; (e) proton therapy<\/strong> Hitachi PROBEAT + Varian ProBeam para sarcoma pedi\u00e1trico + base de cr\u00e2nio + paraespinhal.<\/p>\n

Hospital com 50-150 RTs STS\/ano + 15-50 IORT\/brachy \u00d7 R$ 5-15k = R$ 325k-2.25M\/ano em RT STS + livro CNEN.<\/p>\n

A chemo + TKI + targeted: o est\u00e1gio Lista C5 sist\u00eamico<\/h2>\n

A terceira camada \u00e9 o sist\u00eamico. Padr\u00e3o setorial inclui (a) doxorrubicina Adriamycin<\/strong> Pfizer 60-75mg\/m\u00b2 + ifosfamida<\/strong> 6-12g\/m\u00b2 + dacarbazina<\/strong> AIM regimen Lista C5; (b) trabectedina Yondelis<\/strong> PharmaMar 1.5mg\/m\u00b2 infusional 24h Lista C5 R$ 18-35k\/dose para leiomio + lipossarcoma; (c) eribulina Halaven<\/strong> Eisai 1.4mg\/m\u00b2 + pazopanib Votrient<\/strong> Novartis multikinase 800mg\/dia + regorafenib Stivarga<\/strong> Bayer Lista C5; (d) GIST targeted<\/strong> imatinib Glivec + sunitinib Sutent + ripretinib Qinlock + avapritinib Ayvakit Lista C5 R$ 12-30k\/m\u00eas \u00d7 meses-anos; (e) NTRK fusion<\/strong> larotrectinib Vitrakvi + entrectinib Rozlytrek Lista C5.<\/p>\n

Hospital com 100-300 STS adultos \u00d7 R$ 15-30k\/m\u00eas \u00d7 6-24 meses = R$ 9-216M\/ano em sist\u00eamica Lista C5.<\/p>\n

Tr\u00eas perfis de PGRSS para STS adulto<\/h2>\n

PGRSS gen\u00e9rico subdimensionado.<\/strong> Sem cobertura espec\u00edfica para endopr\u00f3tese + RT IORT\/brachy + Lista C5. Custo mensal R$ 9.000-20.000<\/strong>, efic\u00e1cia limitada.<\/p>\n

PGRSS dedicado intermedi\u00e1rio.<\/strong> Cobertura para ressec\u00e7\u00e3o + chemo, sem endopr\u00f3tese + IORT + targeted. Custo mensal R$ 20.000-35.000<\/strong>, efic\u00e1cia 100-200%.<\/p>\n

PGRSS dedicado completo STS adulto.<\/strong> Ressec\u00e7\u00e3o R0 + endopr\u00f3tese + RT IORT\/brachy + chemo + targeted + GIST + integra\u00e7\u00e3o com PGRSS de pedi onc<\/a>. Custo mensal R$ 35.000-52.000<\/strong>, ROI 250-500%.<\/p>\n

Os tr\u00eas erros que aparecem em PGRSS STS adulto subdimensionado<\/h2>\n

O primeiro \u00e9 o subdimensionamento de endopr\u00f3tese oncol\u00f3gica<\/strong>. Stanmore + Implantcast + Howmedica R$ 80-150k \u00e9 tecnovigil\u00e2ncia obrigat\u00f3ria + livro RBI 10y.<\/p>\n

O segundo \u00e9 a aus\u00eancia de Lista C5 trabectedina + Yondelis<\/strong>. R$ 18-35k\/dose com cofre + cadeia fria + livro 344 + REMS PharmaMar.<\/p>\n

O terceiro \u00e9 a descarte de IORT Mobetron + brachy Ir-192 como Grupo D<\/strong>. IORT + Ir-192 R$ 4-12k \u00e9 radioativo + livro CNEN-NN-3.05.<\/p>\n

A regula\u00e7\u00e3o de PGRSS no Brasil est\u00e1 em fase de moderniza\u00e7\u00e3o t\u00e9cnica acelerada com STS adulto como prioridade. As institui\u00e7\u00f5es que estruturam PGRSS dedicado desde o in\u00edcio \u2014 alinhadas com calend\u00e1rio 2026 de compliance<\/a> \u2014 atravessam o crescimento sem solavanco. Para gestores que precisam alinhar com gest\u00e3o paralela industrial, o portal Seven Res\u00edduos sobre servi\u00e7os completos<\/a> traz a perspectiva integrada. A SBCO Sociedade Brasileira de Cirurgia Oncol\u00f3gica<\/a> \u00e9 refer\u00eancia t\u00e9cnica.<\/p>\n

Solicite cota\u00e7\u00e3o PGRSS de sarcoma partes moles<\/a><\/strong> \u2014 cap\u00edtulo dedicado a leiomiossarcoma + lipossarcoma + GIST + sarcoma sinovial, ressec\u00e7\u00e3o R0 + reconstru\u00e7\u00e3o + endopr\u00f3tese Stanmore\/Implantcast MUTARS Growing\/Howmedica, RT neoadj\/adj + IORT Mobetron\/Liac + brachy Ir-192 + proton therapy, doxorrubicina+ifosfamida+dacarbazina+trabectedina Yondelis+eribulina Halaven+pazopanib Votrient Lista C5, GIST imatinib Glivec+sunitinib Sutent+ripretinib Qinlock+avapritinib Ayvakit + NTRK larotrectinib Vitrakvi.<\/p>\n","protected":false},"excerpt":{"rendered":"

Sarcoma partes moles gera RSS espec\u00edfico \u2014 adulto, ressec\u00e7\u00e3o, RT, TKI. PGRSS dedicado.<\/p>\n","protected":false},"author":3,"featured_media":2160,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[2993,2994,2992,2995],"class_list":["post-2161","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance-legislacao","tag-partes-moles","tag-pazopanib","tag-sarcoma","tag-trabectedina"],"_links":{"self":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2161","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/comments?post=2161"}],"version-history":[{"count":1,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2161\/revisions"}],"predecessor-version":[{"id":4305,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2161\/revisions\/4305"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media\/2160"}],"wp:attachment":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media?parent=2161"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/categories?post=2161"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/tags?post=2161"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}